Podium to Practice: Chicago 2025 – GU: COMRADE

Podium to Practice: Chicago 2025 – GU: COMRADE

Podium to Practice: Chicago 2025
Explore more from your favourite experts – click their name to access their entire library of content.
Icon Chair Speaker

Chair

Dr. Sebastien Hotte

Icon Chair Speaker

Speakers

Dr. Nimira Alimohamed

Dr. Maria Jiang

Studies / Trials Discussed

5007 – A multicenter, randomized, phase 2, investigator-initiated ETCTN trial of olaparib + radium-223 vs. radium-223 in men with castration-resistant prostate cancer (CRPC) with bone metastases (BM) (COMRADE): Initial efficacy and biomarker analysis.

This program has been made possible through unrestricted support from Ipsen.

Studies/trials discussed:

5007 – A multicenter, randomized, phase 2, investigator-initiated ETCTN trial of olaparib + radium-223 vs. radium-223 in men with castration-resistant prostate cancer (CRPC) with bone metastases (BM) (COMRADE): Initial efficacy and biomarker analysis.
Tagged